Adverse reactions associated with sumatriptan

Luman, W; Gray, R. S.; MacLean, Margaret R.; Smith, Gordon C. S.; Templeton, A.G.B.; Lloyd, D K; Simmons, Valerie

doi:10.1016/0140-6736(93)92449-4

Cited by 31 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who experience chest pain/pressure/tightness or symptoms suggestive of angina following triptan assumption should be evaluated for coronary artery disease or Prinzmetal's angina before receiving additional doses 9 …”

Section: Discussionmentioning

confidence: 99%

Acute Myocardial Infarction With Sumatriptan: A Case Report and Review of the Literature

Chalaupka¹

2009

Headache

View full text Add to dashboard Cite

We report a case of myocardial infarction associated with the use of sumatriptan and review the literature regarding similar cases. A 54-year-old woman with a history of migraine without aura, mild arterial hypertension, depression, and no history of coronary artery disease was admitted to our hospital for acute myocardial infarction, 30 minutes after using 6 mg of subcutaneous sumatriptan. Coronary angiography performed several days later revealed a normal coronary arterial system. Although at discharge the patient was advised to permanently avoid triptans, she continued the use of oral sumatriptan at low dosage (25-50 mg) without any problems.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute Myocardial Infarction With Sumatriptan: A Case Report and Review of the Literature

Chalaupka¹

2009

Headache

View full text Add to dashboard Cite

show abstract

“…Peripheral vasospastic complications of ergotamine have been successfully treated with vasodilators and intravenous fluid administration [9]. It is possible that the sedation and weakness caused by sumatriptan therapy [10] delayed the diagnosis of an evolving stroke in this patient, however it is important to note that neurological complications bear no relationship with the elimination serum half-life of sumatriptan [5]. The neurological manifestations resulting from drug induced cerebral vasospasm is potentially reversible by early recognition, fluid administration and nimodipine therapy.…”

Section: Discussionmentioning

confidence: 99%

“…However sumatriptan therapy has been associated with transitory neurological deficit [5]. Sumatriptan is a specific 5-hydroxytryptaminel-like (5-HTl-like) receptor agonist.…”

Section: Discussionmentioning

confidence: 99%

Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan

Jayamaha

Street

1995

Intensive Care Med

View full text Add to dashboard Cite

show abstract

“…In addition, since all triptan drugs are known to have vasoconstrictor activity, they are contraindicated in patients with vascular disease (Longmore, Dowson et al 1999). This practice is highly recommended because of the possibility of serious cardiovascular events, such as myocardial infarction (Mueller, Gallagher et al 1996), cardiac arrhythmia (Ottervanger, van Witsen et al 1994), and stroke (Luman and Gray 1993; Cavazos, Caress et al 1994). Thus, although the triptans are superior to other drugs for the acute treatment of migraine, there remains a significant number of migraineurs who are unable to be successfully treated with these drugs.…”

Section: ) Serotonergic Agonistsmentioning

confidence: 99%

Pharmacology

Bolay,

Durham

2010

Handbook of Clinical Neurology

View full text Add to dashboard Cite

Headache treatment has been based primarily on experiences with nonspecific drugs such as analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), or drugs that were originally developed to treat other diseases such as beta blockers and anticonvulsant medications. A better understanding of the basic pathophysiological mechanisms of migraine and other types of headache has led to the development over the past two decades of more target specific drugs. Since activation of the trigeminovascular system and neurogenic inflammation are thought to play important roles in migraine pathophysiology, experimental studies modeling those events successfully predicted targets for selective development of pharmacological agents to treat migraine. Basically, there are two fundamental strategies for the treatment of migraine, abortive or preventative that is based to a large degree on the frequency of attacks. The triptans, which exhibit potency towards selective serotonin receptors expressed on trigeminal nerves, remain the most effective drugs for the abortive treatment of migraine. However, numerous preventative medications are currently available that modulate the excitability of nervous system, particularly the cerebral cortex. In this chapter, the pharmacology of commercially available medications as well as drugs in development that prevent or abort headache attacks will be discussed.

show abstract

Adverse reactions associated with sumatriptan

Cited by 31 publications

References 9 publications

Acute Myocardial Infarction With Sumatriptan: A Case Report and Review of the Literature

Acute Myocardial Infarction With Sumatriptan: A Case Report and Review of the Literature

Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan

Pharmacology

Contact Info

Product

Resources

About